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Abstract We have retrospectively reviewed toxicities and
response of a cohort of primary central nervous system
lymphoma (PCNSL) patients treated with high dose paren-
teralmethotrexate(MTX)monotherapywithoutwholebrain
radiation.FromTheMassachusettsGeneralHospital(MGH)
Cancer Registry, active since 1946, we selected all immu-
nocompetent patients with histologic and/or radiographic
PCNSLdiagnosedbetween1980and2007.Weidentiﬁedthe
recipients of MTX with leucovorin rescue as sole therapy.
No patient received radiation therapy (XRT). We analyzed
this cohort for toxicity, response and patterns of recurrence.
The cohort of 121 patients received on average 11 cycles of
intravenous MTX at a median dose of 8 g/m
2. Median
interval between cycles was 10 days. After 3 months of
therapy, the overall response rate was 85% (58% CR, 27%
PR).Theoverallsurvival(OS)forthecohortwas7 yearsand
progression-free survival (PFS) was 3.14 years. A trend
toward a higher PFS was seen in patients who continued to
receive MTX (3.48 years) every three months as compared
to patients who ceased MTX after one year (2.86 years). Of
68 patients who achieved initial CR, there were 40 recur-
rences. Twenty-six of the 40 were re-induced with MTX as
above; Sixty-nine percent again achieved CR. Eighty-one
treatment-related toxicities occurred in 1316 MTX cycles.
ThesetoxicitiesincludedMRIwhitematterchanges(N = 8)
and lead to MTX cessation in 16 patients. High-dose MTX
monotherapy of PCNSL is well-tolerated and provides PFS
of[3 years and OS[7 years.
Keywords Methotrexate (MTX)  PCNSL 
Chemotherapy  Lymphoma
Introduction
The rise in prevalence of primary central nervous system
lymphoma has provided the base for accrual to novel
therapies as well as evidence-based treatment options. In
general, over half of primary central nervous system
lymphoma (PCNSL) patients achieve complete response
therapy with overall survival exceeding two years [1].
Anti-folate agents, developed at the NCI in the 1960’s,
demonstrated activity in tumor cell screening assays [2, 3]
and in treatment of systemic B cell lymphoma [4–6].
Methotrexate (MTX) was adopted to treat PCNSL as
unlikely to cause signiﬁcant myelosuppression or white
matter toxicity [7]. It’s beneﬁt could be seen with deferred
radiotherapy (XRT). Parenteral MTX was provided either
as two or more cycles prior to XRT [8, 9] or in combination
with other agents [10]. Intent-to-treat studies utilizing
single agent MTX were performed by the consortiums
NABTT [11] and NOA [12, 13] and evaluated in the
elderly [14]. The NABTT and meta-analyses that have
been performed underscore MTX beneﬁt with CR rates in
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retrospectively reviewed our single institution experience
in treating PCNSL. These data serve as a baseline against
which future therapeutic strategies can be compared.
Methods
Cohort ascertainment
The Massachusetts General Hospital Cancer Registry since
1946 records all newly conﬁrmed malignant tumors diag-
nosed. These data are archivedinan IRB-approved database
and an electronic medical record system. We queried this
database for records of patients with PCNSL treated at the
Massachusetts General Hospital (MGH) between January 1,
1980 and August 1, 2007. We included non-Hodgkin’s
lymphoma (‘‘Large-cell lymphoma’’, ‘‘immunoblastic lym-
phoma’’ and ‘‘NHL of nervous system’’) [15] of the central
nervous system conﬁrmed by pathologic examination.
Pathologicdiagnoseswerenotre-conﬁrmed.Allpatientshad
mass lesions (MRI) of brain, ventricles or meninges in the
setting of pathologic conﬁrmation of lymphoma of brain
parenchyma, CSF, nerve roots and/or spinal cord, or clonal
immunoglobulin gene rearrangement [16], ﬂow cytometry,
or cytologic (‘‘atypical’’ or ‘‘suspicious’’ or ‘‘malignant’’)
abnormalities of cells from CSF or vitreous. We included
patients with conﬁrmed involvement of brain, CSF, nerve or
spinal cord, in the setting of previous intraocular lymphoma
(PIOL), as well as PCNSL patients who later relapsed in
brain or CSF. We excluded patients lacking histologic con-
ﬁrmation. immunocompromised patients; those with HIV
positivity or recipients of organ transplant, those with CNS
low-grade lymphoma or acute leukemia, systemic lym-
phoma(NHL)withspreadtothecentralnervoussystem.We
recorded comorbidities.
Treatment
Of 209 PCNSL patients we selected 121 whose ﬁrst ther-
apy was HD-MTX every ten-14 days) [11, 17]. Of these 67
have been the subject of reports [7, 9, 11]. We excluded
those with multi-drug chemotherapy that was MTX-based;
recipients of[5 standard fractions of whole-brain irradia-
tion (WBXRT) or recipients of alternative dosing sched-
ules of MTX. Prior to 1995, MTX was provided to nine
patients at dose level 3.5 g/sq.m. Thereafter dosing was
8 g/sq.m. every ten to fourteen days until disease pro-
gression or CR. A subgroup of CR patients continued to
receive MTX every month for three cycles and then every
three months thereafter (‘‘maintenance’’). MTX dosing for
all patients was adjusted to pre-treatment calculated or
measured glomerular ﬁltration rate. Leucovorin calcium
rescue (25 mg every 6 h) was initiated 24 h after the start
of MTX infusion and continued until 24 h after MTX
levels fell below\.25 mcM/l. No complete responder
received further corticosteroids.
Outcome measures
We sought to determine the beneﬁt of MTX therapy for
PCNSL of brain. We deﬁned the date of progression as the
date (after CR or PR) of provision of the next form of sys-
temic chemotherapy. These treatments at recurrence inclu-
ded retreatment with MTX (systemic MTX, or alternative
route MTX: intrathecal, intravitreal, ‘‘intraocular’’), drugs
other than MTX, radiation therapy (to whole brain or local-
ized radiosurgery [SRS] or spine). All 121 patients had
radiographic measurable disease. Case ascertainment is
depicted in Fig. 1.
Toxicity
We recorded adverse events that resulted in delay, reduc-
tion or cessation of MTX therapy. These included[grade 2
CTC toxicities (NCI toxicity criteria), leukoencephalopa-
thy (in the absence of gadolinium-enhancing tumor); leu-
kopenia (White blood cell count B3,000 or ANC B1,500);
thrombocytopenia (Platelet counts B75,000); azotemia
(Creatinine C1.5 9 ULN); anaphylactic reaction or gen-
eralized eruption; hepatic dysfunction (SGOT or Alkaline
phosphatase elevation[2.5 9 ULN); or newly appearing
changes in cognition or sensation. We deﬁned leukoen-
cephalopathy[grade 2 (moderate increase in subarachnoid
space (SAS); and/or moderate ventriculomegaly; and/or
focal ﬂair or T2 hyperintensities extending into centrum
ovale; or involving 1/3 to 2/3 of susceptible areas of
cerebrum) and identiﬁed patients with 10% decrement in
Mini-mental status exam as performed every two weeks
prior to CR and every two months thereafter).
Response to therapy
Response to therapy, based upon two-dimensional mea-
surements of gadolinium enhancing mass(es) on MRI or
CT (if MRI contraindicated) at bi-monthly intervals
included: Complete response ([CR]—complete absence of
gadolinium enhancing mass(es)), Partial response ([PR]—
less than complete reduction of enhancing mass(es)),
Mixed response ([MR]—variable change of multiple
masses including progression with concomitant PR or CR),
Stable disease ([SD]—No change in size of a mass), Pro-
gressive disease ([PD]—increased diameter of enhancing
gadolinium mass(es)). Persisting enhancement at the prior
biopsy site was not viewed as progression. We recorded the
date of best response after start of MTX as well as the sites
of failure.
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We recorded patient age, gender, annualized risk of
PCNSL, patient comorbidities, drug toxicities and response
to therapy. Patients were not contacted and thus we
recorded the interval from diagnosis to last follow-up.
Patients lost to follow-up after Cycle 1 MTX, were
assigned survival of ‘‘zero’’ months. Their toxicity data
were recorded. We calculated progression-free survival
(PFS) and overall survival (OS) for all patients.
Results
209 patients were diagnosed with primary central nervous
system lymphoma between January 1, 1980 and August 1,
2007. The case-incidence peak occurred 1996–2000. One
hundred twenty-one patients received MTX monotherapy,
of whom 117 had data for survival evaluation (Fig. 2).
Demographics
The median age of the 121 patients was 63 years (range 23–
86 years). Males predominated (53%). Brain parenchymal
involvement was most common (94%) including 11% with
brain and another nervous system site. Six percent of patient
had CSF involvement with nodular measurable disease.
Comorbidity included: lupus erythematosus prior MTX
therapy (one for ‘‘breast cancer’’ and one for unconﬁrmed
‘‘ocular lymphoma’’), renal insufﬁciency (2), idiopathic
thrombocytopenic purpura (2), polyglandular autoimmune
syndrome E type 1 (1), steroid use (10), non-brain radiation
therapy for systemic malignancy (3) and ocular lymphoma
[4]), prior chemotherapy (7) and Lyme disease (2).
Ocular MHL only 
Histologically-proven 
PCNSL  
WBXRT ≥5 fractions as 
initial treatment 
WBXRT <5 fractions then 
MTX monotherapy 
MTX-based multidrug therapy  MTX monotherapy
MTX then WBXRT   MTX monotherapy  
Cancer Registry Search  Authors Records
NHL eye, nerve, brain or 
cord involvement at any time 
Immunosuppressed 
 -HIV  positive 
 -Organ  transplant 
recipient 
HIV negative or 
status not noted 
Systemic or low-grade 
lymphoma prior to 
PCNSL  
Measurable 
disease 
Exclude
Include
Legend
Fig. 1 Schematic of case
ascertainment. NHL non-
Hodgkin lymphoma, dx
diagnosis, IOL intra-ocular
lymphoma, PCNSL primary
central nervous system
lymphoma, CHT chemotherapy,
MTX methotrexate, WBXRT
whole-brain radiation therapy
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123Response to therapy
Of 121 patients, 106 (87.6%) initially received MTX at a
dose of 8 g/m
2 and ﬁfteen (12.4%) received doses of 3.5 g/
m
2 or less. Response was not evaluable in four patients due
to: missing MRI (1 patient), lost to follow-up (1), cessation
of MTX prior to response evaluation (2). An additional
patient, evaluable for response, died of progressive lym-
phoma prior to MTX therapy. The overall response rate to
Methotrexate induction was 85% (100/117). CR occurred
in 58% (58.5% of patients treated at MTX 8 g/m
2 and 50%
at MTX 3.5 g/m
2). CR was achieved after a median of 6
cycles of therapy over an elapsed time of 3 months.
Twenty-seven percent of patients had PR, 7% PD, 5% SD,
and 3% MR. Patients who did not achieve a CR rapidly
progressed. Twenty-seven of the 41 patients who achieved
PR, SD or MR, progressed after two more cycles of MTX
(one month) (Fig. 2).
Six PCNSL patients had MRI measurable tumor in the
setting of CSF with ‘‘atypical’’ or ‘‘suspicious’’ cells. Five
of these achieved CR (2–9 cycles MTX), and one pro-
gressed (1 cycle). Three patients additionally received at
least one cycle of intrathecal therapy and ﬁve received
intravitreal therapy.
The median overall survival (53 deaths and 68 censored)
was 7 years (95% CI of 4.6, 12.8). The survival rates at
1,[5 and 10 years were 86, 58 and 44% respectively
(Fig. 3, OS). For patients achieving CR, the median pro-
gression-free survival was 3.14 years (95% CI of 2.48,
5.18) (Fig. 4, PFS). Thirty percent of the entire cohort
progressed during therapy with MTX (Table 1). Forty
additional patients (59% of those with CR) recurred
14 months (IQR 6.75, 32.5) after complete response.
Patients in CR who continued MTX at least one year fur-
ther fared better than those who stopped within two cycles
of CR. Progression-free survival for the former was
3.48 years (95% CI of 2.16, 5.8; Fig. 4), versus 2.86 years
(95% CI of 1.32 and upper bound not reached; Fig. 4) for
Cohort
(n=117 evaluable responses) 
CR
(n=68, 58%)
PR/MR/SD 
(n=41, 35%) PD
(n=8, 7%) 
Remain 
CR
(n=28)
Recurred
Anytime 
(n=40)
Recurred 
once 
(n=20) 
Thrice 
(n=6) 
Twice 
(n=14) 
Remaining 
PR/MR/SD  
(n=14) 
Eventually PD 
(n=27) 
Median 14 months 
Median 3 months 
Fig. 2 Responses to MTX
monotherapy. CR complete
response, PD progressive
disease, PR partial response,
MR mixed response, SD stable
disease
Fig. 3 Overall survival of cohort (n = 121). Of 121 patients in the
cohort, 53 patients died and 68 survived. The median OS was 7 years
with 95% CI 4.6, 12. The 1, 5 and 10 year OS rates were 86, 58 and
44% respectively. TTP time to progression, 95% CI 95% conﬁdence
interval
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123the latter. Recurrences occurred in brain (68%), vitreous
(5), systemic sites (5), nerve root (2) and CSF (1). Of sixty-
three deaths (through August 1, 2007), 63% resulted from
PCNSL. No deaths were attributable to drug toxicity.
Of CR patients, 40 ultimately recurred including twenty
patients with one recurrence, fourteen with two sequential
recurrences, and six with three recurrences. Twenty-six
patients with relapsed PCNSL were treated again with
MTX monotherapy. Eighteen (69%) again achieved CR
and one achieved PR.
MTX-toxicities included eighty-one events. Sixteen of
these led to drug cessation and 14 to MTX dose reduction
or delay. Toxicities included leukoencephalopathy (8)
(including full-scale IQ decrement by 30 points which led
to MTX cessation); reversible azotemia (21 patients) (of
which four led to MTX cessation and three to dose delay or
Fig. 4 Progression-free survival. a PFS of CR patients (n = 68)—Of
68 patients achieving CR, forty progressed, while 28 (censored)
remained progression-free. The median PFS was 3.14 years with 95%
CI of (2.48, 5.18). The 1, 5 and 10 years PFS rates were 87, 51 and
38%, respectively; b PFS by MTX continuation after CR—For
patients who ceased MTX within two cycles of CR (dotted line), the
median PFS is 2.86 years with 95% CI of (1.32, upper not reached).
The 1, 2 and 5 years rate are 79, 63, and 29% respectively. For
patients who continued MTX after CR (solid line), the median PFS
is 5 years with 95% CI of (3, 9.2). The 1, 2 and 5 years rate are 90,
67, and 43% respectively. PFS progression-free survival; 95% CI
95% conﬁdence interval
Table 1 Recurrence after MTX therapy (n = 117)
Refs. No. Dose MTX g/m
2 Frequency Cycles to response CR (%) PD/SD (%) PFS (months) OS (months)
[12] 37 8 Biweekly 6 29.7 37.8 13.7 25
[14] 10 8 then 3.5 Every 14 days, 3 cycles 9 60 10 18 20
[23] 20 8 then WBXRT q 14–21 days 2 50 25 N/a N/a
[41] 23 8 q. 14 days then WBXRT 6
? 17
?
[42] 4 400 lg (intravitreally) q. 2 weeks Median 7 100 0
[43] 28 100 mg/kg over 3h Then WBXRT 11 21
PD progressive disease, CR complete response, MTX methotrexate, IQR inter-quartile range
Table 2 Literature reports of MTX monotherapy
Recurrences Number of patients
(% of entire cohort)
Pts with PD at any time 35 (29.9%)
Patients recurring
Once 20%
Twice 14%
Three times or more 6%
CRs who recurred 58.8%
Median time from CR to recurrence 14 months
Recurrence while receiving MTX 27 of 49 patients
Recurrence while NOT receiving MTX 13 of 19 patients
Ref reference, MTX methotrexate, iv intravenous, WBXRT whole-
brain radiation therapy, CR complete response, PD progressive dis-
ease, SD stable disease, PFS progression-free survival, OS overall
survival, FU follow-up
J Neurooncol (2010) 98:385–393 389
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123reduction). MTX was continued in four patients despite
elevated liver enzymes (LFT) including one MTX delay.
The 18 occurrences of leukopenia led to drug cessation (1)
dose delays (2) while thrombocytopenia (16) did not.
Sixteen cutaneous drug reactions, included a ﬁxed drug
reaction, did not require discontinuation; but one anaphy-
lactic reaction led to drug cessation. Nine patients ceased
MTX therapy as a result of sepsis (2), renal failure (2),
mucositis (2), pulmonary emboli, clostridium gastroenter-
itis and drug-resistant tachycardia.
Discussion
We report a single-site cohort provided MTX monotherapy
for PCNSL. The therapy provided CR or PR response in
85% and PFS of 3.14 years. The overall survivals of 86%
at one year, 58% at ﬁve years and 44% at 10 years- are
likely low as we assumed death to have occurred on the
date of last follow-up. These data will well serve investi-
gators describing the beneﬁts to PCNSL patients of novel
immunologic or stem cell therapies. Despite initial MTX
responses (CR, PR, MR, SD); 30% of the 117 patients
progressed within 15 months. We were unable to establish,
as has been reported by Ferreri [18], a metric to separate
eventual responders from non-responders despite evaluat-
ing (unpublished) the prognostic roles of demography,
number and volume of brain lesions, pre-therapy perfor-
mance status and MTX pharmacokinetics. Recent studies
[19] suggest correlates of MTX efﬁcacy and toxicity
including pharmacogenomic analyses as well as assays of
the expression of folate carrier channels [20, 21].
Toxicities of MTX were rare and reversible. Sixty-eight
percent of recipients experienced no toxicity; but seven
MTX-related toxic events led to MTX cessation. These
included: leukoencephalopathy, azotemia, leucopenia,
anaphylaxis, sepsis, and mucositis. This low rate reﬂects
care provided by neurologic and chemotherapy nurses with
experience in the provision of hydration in the setting of
brain edema, the knowledge of drug-MTX interactions and
experience in the provision of ‘‘accelerated’’ calcium leu-
covorin emerging during azotemia or the release of MTX
from ‘‘third-spaces’’. These toxicities have been well
documented [22].
Our CR rate of 58% is similar to other reports (Table 2)
including Watanabe [23] (CR = 50%) and Ng [14] (CR6/
10); but unlike that of Herrlinger [13] (CR = 30%).
Uncertain is whether differences reﬂect the comorbidity of
patients or intricacies of MTX administration.
Three months after starting MTX therapy patients can be
declared ‘‘responders’’ or ‘‘non-responders’’. By this eval-
uation (6 cycles MTX) CR was identiﬁed in 58% of
patients; PD was declared somewhat earlier (2 months).
Thus 3 months of MTX therapy represents a baseline
against which investigators may evaluate the efﬁcacy of
adding other agents. MTX—monotherapy is not curative.
Progression of disease was seen in sixty-six percent of
patients with PR, MR or SD and in 59% of those with CR.
Uncertain is whether continuation of MTX-monotherapy
prolongs PFS. The PFS for CR patients who continued
MTX every three months was 3.48 years in comparison to
2.86 years for those who ceased MTX within the ﬁrst year
and similar patients reported by others [12, 14]. These
recurrences do not reﬂect resistance to MTX; as CR fol-
lowed MTX-monotherapy retreatment in eighteen of 26
PCNSL patients who had relapsed. Although MTX-based
multi-drug/irradiation therapies (Table 3) are associated
with PFS rates ranging from 5.6 months [24] (Cytarabine,
Carmustine, etoposide, melphalan with stem cell rescue) to
11 months [25] (Lomustine, procarbazine, Cytarabine and
methylprednisolone) to 77.4 months [26] (receiving ste-
roids, cyclophosamide or etoposide and procarbazine) it is
unlikely that these approaches will be the subject of ran-
domized trials in comparison to MTX-monotherapy. The
multi-drug therapies [24–37] overall survivals are
60 months [5, 27] 50 months [31] 7 months [26] similar to
those we report.
Promising preliminary data suggest efﬁcacy of adding to
MTX the drugs Temodar [33] and Rituxan [38]; the pro-
vision of autologous stem cell transplantation [39, 40] and
low dose brain radiation. These trials are ongoing. Our data
provide a benchmark by which to measure the additive
value of these approaches. Certainly stem cell transplan-
tation appears a logical addition by which to consolidate
the MTX-related CR seen in almost 60% of our MTX
recipients. Our early experience with MTX and Temodar
and Rituxan points to a reduced interval from diagnosis to
CR.
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